Barclays Forecasts Strong Price Appreciation for Insulet (NASDAQ:PODD) Stock

Insulet (NASDAQ:PODD) had its price target raised by investment analysts at Barclays from $150.00 to $165.00 in a research note issued on Friday, Benzinga reports. The firm currently has an “equal weight” rating on the medical instruments supplier’s stock. Barclays‘s price objective would suggest a potential upside of 13.71% from the stock’s current price.

Other analysts also recently issued reports about the company. Oppenheimer downgraded Insulet from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Citigroup increased their price objective on Insulet from $150.00 to $170.00 and gave the stock a “neutral” rating in a research report on Thursday. Benchmark reduced their target price on Insulet from $250.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Weiss Ratings restated a “sell (d+)” rating on shares of Insulet in a research report on Monday, September 21st. Finally, JPMorgan Chase & Co. upped their price target on shares of Insulet from $152.00 to $170.00 and gave the stock a “neutral” rating in a research note on Thursday. Thirteen research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $192.96.

Insulet Stock Performance

NASDAQ:PODD traded down $11.02 during mid-day trading on Friday, reaching $145.10. The stock had a trading volume of 385,956 shares, compared to its average volume of 1,392,775. Insulet has a twelve month low of $126.40 and a twelve month high of $354.88. The business has a 50 day simple moving average of $141.91 and a 200 day simple moving average of $177.34. The firm has a market capitalization of $10.06 billion, a price-to-earnings ratio of 23.59, a PEG ratio of 1.25 and a beta of 1.06. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.83 and a current ratio of 2.51.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.59 by $0.40. The company had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $832.63 million. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The firm’s quarterly revenue was up 19.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.24 EPS. On average, analysts expect that Insulet will post 6.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PODD. OneDigital Investment Advisors LLC bought a new stake in shares of Insulet in the 2nd quarter worth approximately $6,741,000. Headlands Technologies LLC boosted its position in Insulet by 2,041.5% during the 2nd quarter. Headlands Technologies LLC now owns 31,930 shares of the medical instruments supplier’s stock valued at $4,861,000 after purchasing an additional 30,439 shares during the period. Amundi boosted its position in Insulet by 13.6% during the 2nd quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock valued at $77,320,000 after purchasing an additional 60,929 shares during the period. SEB Asset Management AB bought a new position in Insulet during the 1st quarter worth $24,700,000. Finally, Man Group plc bought a new position in Insulet during the 2nd quarter worth $78,746,000.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Third-quarter performance was strong: Insulet reported $842 million in revenue, up 19.2% year over year, and adjusted EPS of $1.99, beating analyst estimates. The company also announced a $1 billion share repurchase program. Insulet CEO discusses growth and competition
• Positive Sentiment: Several firms lifted their price targets. RBC raised its target to $180 and kept an Outperform rating; Bernstein raised its target to $200 and also rated the shares Outperform. RBC raises Insulet price target
• Neutral Sentiment: Other target increases came with Neutral or Market Perform ratings, suggesting analysts see potential recovery but remain measured in their outlook. RBC also described the valuation as attractive while noting a more conservative 2027 outlook. RBC on Insulet valuation and outlook
• Negative Sentiment: The main concern is slower growth expected in 2027. Insulet’s CEO also expects competitors to take some Omnipod market share, raising questions about the pace of future growth despite the latest-quarter beat. Insulet CEO discusses growth and competition

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.